OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
Kadir Eser, Arif Hakan Önder, Emel Sezer, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 23
Kadir Eser, Arif Hakan Önder, Emel Sezer, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 23
Showing 23 citing articles:
Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
Jean‐Luc Raoul, Camille Moreau-Bachelard, Marine Gilabert, et al.
ESMO Open (2023) Vol. 8, Iss. 1, pp. 100880-100880
Open Access | Times Cited: 25
Jean‐Luc Raoul, Camille Moreau-Bachelard, Marine Gilabert, et al.
ESMO Open (2023) Vol. 8, Iss. 1, pp. 100880-100880
Open Access | Times Cited: 25
Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
Francisco Cézar Aquino de Moraes, Caroline R. M. Pereira, Vitor Kendi Tsuchiya Sano, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Francisco Cézar Aquino de Moraes, Caroline R. M. Pereira, Vitor Kendi Tsuchiya Sano, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
Jueun Lee, Sun‐Hong Kwon, Swan Kwon, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2324852-e2324852
Open Access | Times Cited: 15
Jueun Lee, Sun‐Hong Kwon, Swan Kwon, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2324852-e2324852
Open Access | Times Cited: 15
Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real‐World Data
Aaron Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
Aaron Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
Efficacy of cyclin-dependent kinase inhibitors with concurrent proton pump inhibitors in patients with breast cancer: a systematic review and meta-analysis
Zijie Guo, Ziyu Zhu, Mingpeng Luo, et al.
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Zijie Guo, Ziyu Zhu, Mingpeng Luo, et al.
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer
Kaori Takahashi, Ryuji Uozumi, Toru Mukohara, et al.
The Oncologist (2024) Vol. 29, Iss. 6, pp. e741-e749
Open Access | Times Cited: 4
Kaori Takahashi, Ryuji Uozumi, Toru Mukohara, et al.
The Oncologist (2024) Vol. 29, Iss. 6, pp. e741-e749
Open Access | Times Cited: 4
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Elisa Agostinetto, Georg Pfeiler, Dominik Hlauschek, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104096-104096
Open Access
Elisa Agostinetto, Georg Pfeiler, Dominik Hlauschek, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104096-104096
Open Access
Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer
Timothy Schieber, Samantha Steele, Stephanie Collins, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 6, pp. 658-663
Closed Access | Times Cited: 9
Timothy Schieber, Samantha Steele, Stephanie Collins, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 6, pp. 658-663
Closed Access | Times Cited: 9
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer
Dilek Çağlayan, Mehmet Koçak, Çağlayan Geredeli, et al.
European Journal of Clinical Pharmacology (2022) Vol. 79, Iss. 2, pp. 243-248
Open Access | Times Cited: 15
Dilek Çağlayan, Mehmet Koçak, Çağlayan Geredeli, et al.
European Journal of Clinical Pharmacology (2022) Vol. 79, Iss. 2, pp. 243-248
Open Access | Times Cited: 15
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
Marzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
The Breast (2022) Vol. 66, pp. 157-161
Open Access | Times Cited: 14
Marzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
The Breast (2022) Vol. 66, pp. 157-161
Open Access | Times Cited: 14
Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
Hatice Odabaş, Akif Doğan, Melike Özçelik, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 557-557
Open Access | Times Cited: 7
Hatice Odabaş, Akif Doğan, Melike Özçelik, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 557-557
Open Access | Times Cited: 7
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration
Jean‐Luc Raoul, Philip D. Hansten
Cancer Treatment Reviews (2024) Vol. 129, pp. 102794-102794
Closed Access | Times Cited: 2
Jean‐Luc Raoul, Philip D. Hansten
Cancer Treatment Reviews (2024) Vol. 129, pp. 102794-102794
Closed Access | Times Cited: 2
Mitigating the Risk of Drug Interactions in Cancer Patients Taking Oral Anticancer Agents: The Role of a Multidisciplinary Team-Based Medication Reconciliation
Jorge Rodrigues, Paula A. A. P. Marques, Catarina Gomes, et al.
Cureus (2023)
Open Access | Times Cited: 4
Jorge Rodrigues, Paula A. A. P. Marques, Catarina Gomes, et al.
Cureus (2023)
Open Access | Times Cited: 4
The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
Prajakta Patil, Mrunal Desai, Sumit Birangal, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 5, pp. 631-644
Open Access | Times Cited: 1
Prajakta Patil, Mrunal Desai, Sumit Birangal, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 5, pp. 631-644
Open Access | Times Cited: 1
Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
Wei Wang, Jiayi Wu, Keyu Chen, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 3
Wei Wang, Jiayi Wu, Keyu Chen, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 3
The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis
Yu-Cheng Chang, Junmin Song, Yu‐Tzu Chang, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5133-5133
Open Access | Times Cited: 3
Yu-Cheng Chang, Junmin Song, Yu‐Tzu Chang, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5133-5133
Open Access | Times Cited: 3
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
The Breast (2024) Vol. 76, pp. 103761-103761
Open Access
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
The Breast (2024) Vol. 76, pp. 103761-103761
Open Access
Estimation of CDK inhibitors by RP-HPLC: application for pharmacokinetic interactions studies with PPIs
Mrunal Desai, Prajakta Patil, Gautham G. Shenoy, et al.
Bioanalysis (2024), pp. 1-12
Closed Access
Mrunal Desai, Prajakta Patil, Gautham G. Shenoy, et al.
Bioanalysis (2024), pp. 1-12
Closed Access
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials
Amit Rauthan, Ankita Jain, Manmohan Singh, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 3, pp. 395-418
Open Access
Amit Rauthan, Ankita Jain, Manmohan Singh, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 3, pp. 395-418
Open Access
Proton Pump Inhibitors Worsen Colorectal Cancer Outcomes in Patients Treated with Bevacizumab
Chin-Chia Wu, Chuan‐Yin Fang, Wen‐Yen Chiou, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3378-3378
Open Access
Chin-Chia Wu, Chuan‐Yin Fang, Wen‐Yen Chiou, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3378-3378
Open Access
Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments
Fiorenza Santamaria, Michela Roberto, Dorelsa Buccilli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 200, pp. 104405-104405
Closed Access
Fiorenza Santamaria, Michela Roberto, Dorelsa Buccilli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 200, pp. 104405-104405
Closed Access
Side effects of gastrointestinal drugs
Dianne May, Devin L. Lavender, Emily Hightower
Side effects of drugs annual (2023), pp. 365-381
Closed Access | Times Cited: 1
Dianne May, Devin L. Lavender, Emily Hightower
Side effects of drugs annual (2023), pp. 365-381
Closed Access | Times Cited: 1
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer
Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, et al.
Research Square (Research Square) (2022)
Open Access
Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, et al.
Research Square (Research Square) (2022)
Open Access
